ShiftBio, 서울특별시 동대문구 고산자로 568 리스트안암 제2층, Seoul (2026)

21/07/2026

Korea's Ministry of Science and ICT named SHIFTBIO an Excellent Corporate R&D Center for the first half of 2026, one of 27 companies nationwide. 🔬

We work on drug delivery. Not the drug itself, but the system that carries an already-discovered drug to the exact place it needs to reach. The drugs are good. Getting them across the blood-brain barrier or into inflamed tissue, without hitting healthy cells and again on the next dose, is still the hard part. That is what we do.

The designation does not score a product. It looks at the lab itself, at R&D investment, research staff, and the technology it actually produces. In delivery the cargo keeps changing and the carrier has to be redesigned each time, so the real asset is not any one result but a lab that can keep making them. That is what this confirms.

16/06/2026

We’ve moved!🚀
SHIFTBIO has a brand new home at Anam. With expanded lab capacity and state-of-the-art facilities, we are fully equipped to accelerate our drug development pipeline faster than ever.
The science was never our bottleneck—and now, space won't be either.
New headquarters. Same relentless focus.
If you are in the neighborhood, our doors are always open. Drop by for a coffee and a great conversation!

04/06/2026

🎉 Driving Innovation Forward: SHIFTBIO Shines at the 2026 KDDF Global Biotech Showcase!

We are incredibly proud to share that SHIFTBIO was selected to participate and present at the prestigious 2026 KDDF Global Biotech Showcase (GBS) held at the Fairmont Ambassador Seoul!

Among a highly competitive pool of innovators, SHIFTBIO achieved double recognition by being selected for two major exclusive sessions:
1️⃣ Closed CNS-IR Session
We had the privilege of pitching our cutting-edge therapeutic strategies to an exclusive group of global investors and biopharma leaders, spotlighting our advancements in targeting complex Central Nervous System (CNS) disorders.
2️⃣ Innovation Tiger 2026 FAST TRACK
As a featured presenter, we took the main stage to showcase our proprietary NSM Scaffold: Programmable Targeting & Loading platform. We engaged in a high-intensity pitch and a deep-dive Q&A session with the esteemed 'Tiger Panel'—which included global pharma giants and top-tier VCs.

🤝 Shaping the Future of Drug Delivery
The event sparked deeply meaningful, high-value discussions with global pioneers who share our vision. The immense interest in our programmable Natural Nanoparticle (NNP) platform reinforces our commitment to overcoming the historical limits of tissue-specific drug delivery.

A huge thank you to the Korea Drug Development Fund (KDDF) for hosting such a phenomenal platform for global partnering.

The future of medicine is programmable, and SHIFTBIO is leading the charge!🌍🌟

03/06/2026

🚀 Exciting News from SHIFTBIO: Celebrating Double Milestones!

We are thrilled to share two major achievements from the first half of this year that mark a significant leap forward for SHIFTBIO's R&D ecosystem.

SHIFTBIO’s Corporate R&D Center has been officially:
- Selected as an "Excellent Corporate R&D Center"
- Designated as a "Military Service-Designated Organization" (for Technical Research Personnel / 전문연구요원)

These prestigious recognitions lay a solid foundation for top-tier talents in science and engineering to join our journey and drive impactful innovation.

At SHIFTBIO, we are pioneering a programmable Natural Nanoparticle (NNP) platform designed for the tissue-specific delivery of diverse therapeutic modalities. This milestone reflects our relentless commitment to advancing R&D capabilities and creating a nurturing environment where passionate young researchers can gain meaningful, hands-on experience.

We invite brilliant minds who wish to innovate and grow alongside SHIFTBIO to explore our journey. Keep an eye on our upcoming opportunities!

---
🚀 [시프트바이오] 상반기, 기쁜 두 가지 소식을 전해드립니다!

시프트바이오의 R&D 역량과 연구 환경을 한 단계 도약시킬 올해 상반기의 기쁜 성과를 공유합니다.

시프트바이오 기업부설연구소가 아래의 두 가지 핵심 기관으로 선정되었습니다.
- '우수기업부설연구소' 선정
- '대한민국 병역지정업체(전문연구요원)' 선정

이번 선정을 통해 대한민국을 이끌어갈 우수한 이공계 인재들이 시프트바이오에 합류하여 함께 연구하고 성장할 수 있는 든든한 토대를 마련하게 되었습니다.

시프트바이오는 다양한 치료 물질의 조직 특이적 전달을 가능하게 하는 프로그래머블 Natural Nanoparticle (NNP) 플랫폼을 개발하고 있습니다. 이번 성과는 당사의 지속적인 R&D 역량 강화 노력뿐만 아니라, 젊은 연구 인재들이 의미 있는 실무 연구 경험을 통해 역량을 마음껏 펼칠 수 있는 최적의 환경을 만들어가겠다는 의지의 결실입니다.

혁신적인 신약 전달 플랫폼의 미래를 시프트바이오와 함께 만들어갈 우수한 연구 인재들의 많은 관심과 지원을 부탁드립니다.
#시프트바이오 #기업부설연구소 #병역지정업체 #전문연구요원 #대체복무 #바이오텍 #약물전달

19/05/2026

We are delighted to announce that SHIFTBIO participated in ASGCT 2026, the Annual Meeting of the American Society of Gene and Cell Therapy. At this meeting, our CEO Gi-Hoon Nam presented the latest progress across SHIFTBIO's delivery platform.

We introduced I-NNP, our delivery platform developed for immunology programs, and shared systemic delivery data for both RNA and protiens. We were especially proud to unveil NNP Design AI for the first time. NNP Design AI is our AI-driven approach to designing cell-derived delivery particles, transforming uncertainty into predictability.

Looking ahead, SHIFTBIO will present its B-NNP brain-targeted delivery platform as a poster at AAIC 2026. Stay tuned for SHIFTBIO's upcoming journey!

04/05/2026

Anti-CD47 antibodies have stalled. The target has not.

Our new Kidney International paper reports an engineered vesicle displaying a high-affinity SIRPα variant on its surface, designed to engage circulating CD47+ myeloid cells in acute kidney injury before they infiltrate the renal parenchyma.

In two AKI models, a single intravenous dose reduced BUN, creatinine, and NGAL, and reprogrammed macrophages toward a pro-resolving phenotype.

The platform combines multivalent surface display, active cellular internalization, and selective enrichment on disease-relevant immune cells. These are capabilities a monoclonal antibody does not have.

That is the asset today.

The same surface-engineering strategy extends as a delivery platform for next-generation immunology payloads, including A*O and siRNA.

Therapeutic on its own. Delivery vehicle for what comes next.

Kidney International 2026, 109:545-558.

29/12/2025

SHIFTBIO is proud to announce the publication of our latest research on our Inflammation-targeted Natural Nanoparticle (I-NNP) platform, SIRP-NNP, in the prestigious journal Kidney International. This milestone highlights our platform’s potential to redefine the treatment of Acute Kidney Injury, a condition currently lacking disease-specific therapies.

By introducing engineered SIRP-NNP, we have established a novel therapeutic approach that specifically targets CD47-overexpressing myeloid cells within the bloodstream. Unlike traditional tissue-specific delivery, our strategy focuses on therapeutic reprogramming at the systemic level. By modulating the CD47-SIRP interaction, we intercept and transform circulating immune cells into pro-resolving phenotypes before they can infiltrate and damage organ tissues. This NNP-based strategy actively promotes tissue repair while providing a scalable and safer alternative to conventional cell-based therapies, presenting a promising path for clinical translation and large-scale manufacturing.

In addition to therapeutic efficacy, our study highlights the potential of urinary CD47 as a non-invasive biomarker. This discovery offers a new tool for early detection and real-time monitoring of kidney injury.
We invite our partners and the scientific community to explore how SHIFTBIO is leveraging advanced NNP engineering to lead the next wave of treatments for inflammatory diseases!

For more information: https://www.kidney-international.org/article/S0085-2538(25)01022-1/abstract

03/11/2025

We are thrilled and honored to share that our CEO, Prof. Gihoon Nam, was an invited speaker at Dassault Systèmes’ Science Week 2025 in Boston! 🎤🌟

During his talk, Prof. Nam showcased the progress of our AI-driven drug-delivery platform, developed on Dassault’s 3DEXPERIENCE through a powerful three-year collaboration with BIOVIA. He also shared our broader vision to leverage Dassault’s Virtual Twin Experience across the entire drug-development lifecycle, from discovery and CMC to clinical studies and final approval.

To make this vision a reality, ShiftBio is expanding our foundational partnership with Dassault Systèmes and deepening our collaboration with the BIOVIA Research Team to overcome the delivery void with our platform.

Our ultimate goal is to become a flagship reference, a small biotech that fully embraces the power of the 3DEXPERIENCE ecosystem, seamlessly connecting the virtual and real worlds from discovery through full development.

This vision reflects our shared belief that digital AI and simulation are no longer optional: they are essential to meaningful innovation. 🚀

31/10/2025

Celebrating Science, Collaboration, and Innovation!

At the 2025 DIPS Global Tech Con, Dr. Yoonjeong Choi represented SHIFTBIO, introducing our AI-Driven Natural Drug Delivery Platform — a next-generation technology that merges biological insight with digital intelligence.

Together with distinguished experts, she explored how AI can accelerate drug development and how global collaboration can fuel the next wave of biomedical innovation.

We’re excited to be part of this global movement shaping the future of therapeutics.

ShiftBio

21/07/2026

16/06/2026

04/06/2026

03/06/2026

19/05/2026

04/05/2026

29/12/2025

03/11/2025

31/10/2025

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category

Listing takedown request